emlenoflast   Click here for help

GtoPdb Ligand ID: 12172

Synonyms: Inzomelid | MCC-7840 | MCC7840
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Emlenoflast (MCC7840 [2]; formerly IZD 174) is one of a growing number of NLRP3 inflammasome inhibitors that have been developed for anti-inflammatory potential [3]. It was developed by Inflazome (acquired by Roche in 2020) as an orally bioavailable drug that is able to cross the blood-brain barrier.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 101.47
Molecular weight 388.16
XLogP 3.6
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(NS(=O)(=O)c1ccn(n1)C(C)C)Nc1c2CCCc2cc2c1CCC2
Isomeric SMILES CC(C)n1ccc(n1)S(=O)(=O)NC(=O)Nc1c2CCCc2cc2c1CCC2
InChI InChI=1S/C19H24N4O3S/c1-12(2)23-10-9-17(21-23)27(25,26)22-19(24)20-18-15-7-3-5-13(15)11-14-6-4-8-16(14)18/h9-12H,3-8H2,1-2H3,(H2,20,22,24)
InChI Key MTOUOUSKXWSTAX-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
A phase 1 Safety and Tolerability study of emlenoflast in healthy volunteers has been completed.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04015076 Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With Inzomelid Phase 1 Interventional Inflazome UK Ltd